Archive for the ‘Gene Therapy Research’ Category

Pessac, France Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of NextGeneration Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a bioprinted skin substitute in collaboration with the Assistance Publique Hpitaux de Marseille. Poietis appoints Dr. Geoffrey Gurtner, MD, Johnson and Johnson Professor of Surgery, Professor of Materials Science and Engineering at Stanford University and Vice-Chairman of Surgery for Innovation at Stanford University School of Medicine (California, United States) and Dr. Michael H. May, President & CEO of the Center for Commercialization of Regenerative Medicine (CCRM) at Toronto (Canada).

The formation of Poietis SAB is a very important step towards company global deployment in the clinical area says Bruno Brisson, Poietis co-founder and VP Business Development. We are delighted to welcome Dr. Gurtner and Dr. May to our SAB, where they will be key contributors in further enhancing our efforts to bring bioprinting solutions to clinicians and patients with high unmet needs.

To have Dr. Gurtner, a world-renowned expert in tissue-engineering therapies for skin wound healing, join our SAB will enrich our R&D efforts to achieve the first-in-human of a bioprinted skin substitute in the coming years adds Dr. Fabien Guillemot, CEO and Poietis founder. We also believe Dr. May will prove invaluable to Poietis leadership team, and we look forward to his insights and guidance to accelerate the advancement of our bioprinting platform technology to address the key challenges in tissue manufacturing and regenerative medicine.

3D bioprinting is a once-in-a-generation transformative technology. By focusing its 3D printing platform on a clinical application of high unmet need, Poietis is leading the adoption of 3D printing in cell therapy and tissue engineering comments Dr. Michael H. May, PhD, President & CEO of the CCRM.

Dr. Geoffrey Gurtner, MD, is Johnson and Johnson Professor of Surgery and Professor of Materials Science and Engineering at Stanford University, California; USA. He currently serves as the Associate Chairman for Research in the Department of Surgery and is the Executive Director of the Stanford Wound Care Center.

Geoff is a magna cum laude graduate of Dartmouth College and an AOA graduate of the University of California-San Francisco School of Medicine. He completed a general surgery residency at Massachusetts General Hospital, a plastic surgery residency at NYU School of Medicine and received advanced training in microsurgery at the University of Texas-MD Anderson Cancer Center. He is board certified in both general surgery and plastic surgery. He is the author of over 180 peer-reviewed publications in both scientific and surgical literature and editor for two major textbooks in the field: Grabb & Smiths Plastic Surgery and Plastic Surgery. Geoff was awarded the James Barrett Brown Award (for best paper in plastic surgery) in both 2009 and 2010, and has been named Researcher of the Year by the American Society of Plastic Surgeons and the American Association of Plastic Surgeons. His research has led to the development of several novel biomedical technologies. Geoff has co-founded several start-ups focused on wound healing, aesthetics and cardiovascular health.

Dr. Michael May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship. He is President and Chief Executive Officer of the Center for Commercialization of Regenerative Medicine (CCRM) a Canadian public-private partnership supporting the translation and commercialization of cell & gene therapies and associated enabling technologies through stakeholder networks and with specialized teams, infrastructure and funding. He is also CEO of CCRM Enterprises, the venture creation and investment arm of CCRM.

Prior to CCRM, Michael was the President and co-founder of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity. Rimons initial focus was on advanced wound healing. Michael sits on a number of boards and advisory committees, including: the Entrepreneurship Leadership Council at the University of Toronto; the Commercialization Committee of the International Society for Cell and Gene Therapy, the Alliance for Regenerative Medicine Foundation, CellCan and AgeX Inc. He is Chair of ExcellThera and co-moderates sessions in the health streams of the Creative Destruction Labs.

*****

About Poietis: Bioprinting company specializing in the development of new biomanufacturing solutions, based on Laser-Assisted Bioprinting, for human tissues. Poietis mission is to provide clinicians and patients with tissue engineering therapies thanks to its innovative, proprietary Next-Generation Bioprinting platform (NGB). The multimodal NGB platform is declined in two versions: one for in vitro tissue engineering research (NGB-R) and a clinical version (NGB-C) for the production of implantable bioprinted tissues. This multi-modal, automated biomanufacturing platform enables researchers to achieve superior tissue through high resolution, and enables the fabrication of complex tissues with repeatability and reproducibility. Poietis bioprinting technology is the result of innovative research carried out over ten years at Inserm and the University of Bordeaux. Poietis won the iLab competition in 2014, the World Innovation Challenge Phase II in 2017 and recently the EY Disruptive Strategy Award. The company currently employs 35 people. More information: http://www.poietis.com Contact : bruno.brisson@poietis.com

Read more:
Poietis Announces Formation of Scientific Advisory Board and Appoints Two First Prominent Regenerative Medicine Experts - BioSpace

The chapter of global growth trends of this Gene Therapy Products Market business report includes industry tendencies, the growth proportion of major producers, and production analysis while studying market size by application. It covers market consumption analysis by application and studies market size by type, analysis of value, product utility, market percentage & production market share by type. Analysis of profiles of manufacturers or commanding players of the global market is performed based on sales area, key products, gross margin, revenue, price, and production. Market value chain and sales channel analysis of this market document includes details of customer, distributor, market value chain, and sales channel analysis.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-gene-therapy-products-market

Global gene therapy products market is set to witness a substantial CAGR in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Rising cancer cases and unused potential for emerging markets are the major factors for the growth of this market.

Few of the major competitors currently working in the globalgene therapy products marketareAdaptimmune., Anchiano Therapeutics, bluebird bio, Inc., CELGENE CORPORATION, GlaxoSmithKline plc., Merck KGaA, Novartis AG, Achieve Life Sciences, Inc., Spark Therapeutics, Inc., Abeona Therapeutics, Inc, Adverum, agtc, Arbutus Biopharma, Audentes Therapeutics, AveXis, Inc., CRISPR Therapeutics, Intellia Therapeutics, Inc and Gilead Sciences,Inc. among others.

Market Definition:Global Gene Therapy Products Market

Gene therapy or human gene therapy is a process which is used to modify gene for the treatment of any disease. Plasmid DNA, bacterial vector, human gene editing technology and viral vectors are some of the most common type of gene therapy products. The main aim of the gene therapy is to replace the dysfunctional genes. Somatic and germline are some of the most common type of the gene therapy.

Complete report on Global Gene Therapy Product Market Research Report 2019-2026 spread across 350 Pages, profiling Top companies and supports with tables and figures

Segmentation: Global Gene Therapy Products Market

Gene Therapy Products Market : By Product

Gene Therapy Products Market : By Application

Gene Therapy Products Market : ByGeography

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-gene-therapy-products-market

Key Developments in the Gene Therapy Products Market:

Gene Therapy Products Market Drivers

Gene Therapy Products Market Restraints

Competitive Analysis: Gene Therapy Products Market

Global gene therapy products market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of gene therapy products market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key questions answered in the report :-

To get this report at an attractive cost, click herehttps://www.databridgemarketresearch.com/speak-to-analyst?dbmr=global-gene-therapy-products-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

More:
Covid-19 Impact On Global Gene Therapy Products Market 2020 : Industry Trends, Size, Growth, Swot Analysis By Top Key Players And Forecast Report To...

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPHE100001165/

MARKET INTRODUCTION

Gene therapy is the introduction of DNA into a patient to treat a genetic disease or a disorder. The newly inserted DNA contains a correcting gene to correct the effects of a disease, causing mutations. Gene therapy is a promising treatment for genetic diseases and also includes cystic fibrosis and muscular dystrophy. Gene therapy is a suitable treatment for infectious diseases, inherited disease and cancer.

MARKET DYNAMICSThe growth of the gene therapy market is regulated due to various reason which includes the rapid involvement of synthetically modified gene to treat various diseases, it helps in designing the personalized medicine, rise in the research and development of the gene therapy among the others. The gene therapy requires less doses of medicines and is one time treatment, this factor is likely to show growth opportunity for gene therapy market in coming near future.

The report also includes the profiles of key gene therapy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Key Competitors In Market areSangamo Therapeutics, Inc., bluebird bio, Inc., uniQure N.V., AveXis, Inc., Vineti, Solid Biosciences., Spark Therapeutics, Inc., CHIMERON BIO, RENOVA THERAPEUTICS, HORAMA S.A.

TOC of Market Report Contains:

MARKET SCOPE

The Global Gene Therapy Market Analysis to 2027 is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of gene therapy market with detailed market segmentation by cell type, application and geography. The global gene therapy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading gene therapy market players and offers key trends and opportunities in the market.

Market segmentation:

Gene Therapy Market to 2027 Global Analysis and Forecasts by Cell Type (Somatic Gene Therapy, Germline Gene Therapy); By Application (Genetic Disorder, Cancer, Neurological Disorder, and Others)

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

Points Covered in The Report:

Click to buy full report with all description:-https://www.theinsightpartners.com/buy/TIPHE100001165/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

See original here:
COVID-19 Impact on GENE THERAPY MARKET EXPECTED 2020 WITNESS A SUSTAINABLE GROWTH OVER 2027 WITH SANGAMO THERAPEUTICS, INC., BLUEBIRD BIO, UNIQURE NV,...

Gene Therapy for CNS Disorders Market Insights 2018, is a professional and in-depth study on the current state of the global Gene Therapy for CNS Disorders industry with a focus on the Global market. The report provides key statistics on the market status of the Gene Therapy for CNS Disorders manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2018-2025 global Gene Therapy for CNS Disorders market covering all important parameters.

The report on the Gene Therapy for CNS Disorders market provides a birds eye view of the current proceeding within the Gene Therapy for CNS Disorders market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Gene Therapy for CNS Disorders market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Gene Therapy for CNS Disorders market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601445&source=atm

The key points of the Gene Therapy for CNS Disorders Market report:

The report provides a basic overview of the Gene Therapy for CNS Disorders industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2018-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Gene Therapy for CNS Disorders industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2018-2025 market development trends of Gene Therapy for CNS Disorders industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Gene Therapy for CNS Disorders Industry before evaluating its feasibility.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601445&source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Gene Therapy for CNS Disorders are included:

The key players covered in this studyGilead (Kite Pharma)Amgen (BioVex)NovartisRoche (Spark Therapeutics)Bluebird Bio

Market segment by Type, the product can be split intoEx VivoIn VivoMarket segment by Application, split intoHospitalsClinicsOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Gene Therapy for CNS Disorders status, future forecast, growth opportunity, key market and key players.To present the Gene Therapy for CNS Disorders development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Gene Therapy for CNS Disorders are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601445&licType=S&source=atm

Reasons to Purchase this Report:

* Estimates 2018-2025 Gene Therapy for CNS Disorders market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Read the original:
The Economic Impact of Coronavirus on Gene Therapy for CNS Disorders Market : In-depth study on Industry Size and Analysis on Emerging Growth Factors...

LONDON--(BUSINESS WIRE)-- MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research. It is the first publication in which a small activating RNA treatment (MTL-CEBPA) demonstrated clinical benefit. In addition, the Company provided an update on its ongoing clinical trials for lead program MTL-CEBPA and its drug discovery programs.

This landmark publication in Clinical Cancer Research details for the first time that RNA medicines can activate gene expression, providing clinical benefit to patients, commented Robert Habib, CEO of MiNA Therapeutics. As we enter into the second half of 2020, we continue to advance our clinical development objectives and uncover the vast opportunities inherent in our unique drug discovery pipeline.

Publication and OUTREACH Study Update

The publication in Clinical Cancer Research summarizes the results from MiNAs Phase I, open-label, dose escalation and dose expansion trial of MTL-CEBPA, OUTREACH, in adults with advanced Hepatocellular Carcinoma (HCC). Overall, MTL-CEBPA was well-tolerated and demonstrated pharmacodynamic target engagement, meeting the primary endpoint of the study. Furthermore, a reduction of suppressive immune cells in the tumour microenvironment as well as initial signs of potential synergistic efficacy when combined with standard of care tyrosine kinase inhibitors in HCC could be observed. These encouraging Phase I data validate the targeting of C/EBP- as a novel therapeutic strategy in cancer and prompted a Phase Ib study further evaluating MTL-CEBPA in combination with sorafenib in HCC. Enrolment for the Phase Ib part of the OUTREACH trial was completed in Q1 2020 and initial results will be presented during a poster session at the forthcoming American Society of Clinical Oncology (ASCO) on Friday, May 29, 2020. The framework for a subsequent Phase II clinical trial is currently being designed with the objective of initiating this next stage of clinical development in the second half of 2020.

The full Clinical Cancer Research publication is available on the Publications page of MiNAs website. A similar overview of the Phase I data was most recently presented at the European Society for Medical Oncology (ESMO) in September 2019.

TIMEPOINT Update

In March 2020, TIMEPOINT, a global Phase I/Ib clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours was initiated and the first patient was treated. The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients. Recruitment for the study is expected to continue through 2021.

Discovery Programs

In parallel to the clinical trial developments, MiNA is further expanding its drug discovery pipeline with a focus on developing new drug candidates that can address a range of indications including genetic and metabolic diseases. Most recently in January 2020, MiNA validated its metabolic disease capabilities through the entry into a research collaboration with AstraZeneca, a global leader in the discovery and development of prescription medicines to treat metabolic diseases. MiNA remains well-positioned to build out its early-stage pipeline based on its saRNA approach which, through transcriptional activation, enables the modulation of previously undruggable targets.

About MTL-CEBPA

MTL-CEBPA is the first therapy to specifically up-regulate CCAAT/enhancer binding protein alpha (C/EBP-), a transcription factor that acts as a master regulator of myeloid cell lineage determination and differentiation. Dysregulated myeloid cells have been implicated in several diseases and identified as a critical barrier for many therapies to induce clinical responses in solid tumour cancers. In pre-clinical studies MTL-CEBPA has been shown to improve the anti-tumour activity of cancer therapies by targeting dysregulated myeloid cells and reducing their suppression in the tumour microenvironment.

About MiNA Therapeutics

Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients cells. We are applying our technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. http://www.minatx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005028/en/

View post:
MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug...

DetailsCategory: AntibodiesPublished on Wednesday, 27 May 2020 10:34Hits: 305

In CheckMate -9LA, Opdivo + Yervoy combined with two cycles of chemotherapy demonstrated superior overall survival versus chemotherapy, regardless of PD-L1 expression or tumor histology1

Approval marks sixth indication for Opdivo + Yervoy-based combinations across five types of cancer

Two Opdivo + Yervoy-based combinations are now approved in first-line lung cancer

PRINCETON, NJ, USA I May 26, 2020 IBristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.1 The therapy is approved for patients with squamous or non-squamous disease and regardless of PD-L1 expression.1 This application was reviewed under the FDAs Real-Time Oncology Review (RTOR) pilot program, which aims to ensure that safe and effective treatments are available to patients as early as possible.2 On May 15, the FDA approved Opdivo + Yervoy as a first-line treatment for certain patients with metastatic NSCLC whose tumors express PD-L11% as determined by an FDA-approved test.

Approval for Opdivo + Yervoy with limited chemotherapy is based on the pre-specified interim analysis from the Phase 3 CheckMate -9LA trial in which Opdivo + Yervoy combined with two cycles of platinum-doublet chemotherapy demonstrated superior overall survival (OS) versus chemotherapy (hazard ratio [HR] 0.69; 96.71% confidence interval [CI]: 0.55 to 0.87; P=0.0006) regardless of PD-L1 expression or tumor histology (minimum 8.1 months follow up).1,3 Median overall survival (mOS) was 14.1 months (95% CI: 13.2 to 16.2) versus 10.7 months (95% CI: 9.5 to 12.5), respectively.1 In a follow-up analysis at 12.7 months, the hazard ratio improved numerically to 0.66 (95% CI: 0.55 to 0.80), with mOS of 15.6 months (95% CI: 13.9 to 20.0) and 10.9 months (95% CI: 9.5 to 12.5).1,3 At one year, 63% of patients treated with Opdivo + Yervoy with limited chemotherapy and 47% of those treated with chemotherapy were still alive.3

Opdivo is associated with the following Warnings and Precautions including immune-mediated: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, skin adverse reactions, encephalitis, other adverse reactions; infusion-related reactions; embryo-fetal toxicity; and increased mortality in patients with multiple myeloma when Opdivo is added to a thalidomide analogue and dexamethasone, which is not recommended outside of controlled clinical trials.1,4 Please see the Important Safety Information section below, including Boxed WARNING for Yervoy regarding immune-mediated adverse reactions.4

We have come a long way in understanding the role of dual immunotherapy-based approaches in cancer and the potential impact on patients long-term outcomes, said David P. Carbone, MD, PhD, CheckMate -9LA investigator and Director of the James Thoracic Oncology Center at The Ohio State University. The positive findings from CheckMate -9LA demonstrate the benefit of combining dual immunotherapy with limited chemotherapy for NSCLC patients regardless of PD-L1 status. With todays approval, more patients now have access to an Opdivo + Yervoy-based option and a chance at a longer life.1

In the trial, the overall response rate (ORR) per Blinded Independent Central Review (BICR) was 38% (95% CI: 33 to 43) for patients treated with Opdivo + Yervoy with limited chemotherapy and 25% (95% CI: 21 to 30) for patients treated with chemotherapy.

Non-small cell lung cancer is a complex disease that requires multiple treatment options to address the needs of different patient populations,5 said Adam Lenkowsky, general manager and head, U.S., Oncology, Immunology, Cardiovascular, Bristol Myers Squibb. This second approval of an Opdivo + Yervoy-based combination for the first-line treatment of advanced NSCLC now gives more patients access to a dual immunotherapy approach that can be administered with or without limited chemotherapy, depending on the patient and their PD-L1 status, and the possibility of a chance to live longer.1

Opdivo + Yervoy is a unique combination of immune checkpoint inhibitors, featuring a potentially synergistic mechanism of action that targets two different checkpoints (PD-1 and CTLA-4) to help destroy tumor cells: Yervoy helps activate and proliferate T cells, while Opdivo helps existing T cells discover the tumor.1,4,6 Some of the T cells stimulated by Yervoy can become memory T cells, which may allow for a long-term immune response.6,7,8,9,10,11 Targeting of normal cells can also occur and result in immune-mediated adverse reactions, which can be severe and potentially fatal.1 Please see the Important Safety Information section, including Boxed WARNING for Yervoy (ipilimumab) regarding immune-mediated adverse reactions.4

Receiving a diagnosis of advanced lung cancer is devastating,12 said Andrea Ferris, president and chief executive officer, LUNGevity. Todays announcement is welcome news as it provides a new dual immunotherapy-based option for previously untreated patients searching for a treatment that may help extend their lives.1

This application is part of the FDAs Project Orbis initiative, enabling concurrent review by the FDA and the health authorities in Australia, Canada and Singapore.

About CheckMate -9LA

CheckMate -9LA (NCT03215706) is a Phase 3, randomized open-label, multi-center study evaluating Opdivo + Yervoy combined with two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy (four cycles followed by optional pemetrexed maintenance therapy if eligible) as a first-line treatment in patients with metastatic or recurrent NSCLC regardless of PD-L1 expression and histology.1 A total of 361 patients were treated with Opdivo + Yervoy with platinum-doublet chemotherapy until disease progression, unacceptable toxicity or for up to two years.1 A total of 358 patients were treated with platinum-doublet chemotherapy for four cycles and optional pemetrexed maintenance for non-squamous patients (if eligible) until disease progression or toxicity.1 The primary efficacy outcome measure of the trial was OS.1 Additional efficacy outcome measures included progression-free survival, ORR and duration of response as assessed by BICR.1

Select Safety Profile from CheckMate -9LA Study

Serious adverse reactions occurred in 57% of patients.1 Opdivo + Yervoy in combination with platinum-doublet chemotherapy were discontinued for adverse reactions in 24% of patients and 56% had at least one treatment withheld for an adverse reaction.1 The most frequent (>2%) serious adverse reactions were pneumonia, diarrhea, febrile neutropenia, anemia, acute kidney injury, musculoskeletal pain, dyspnea, pneumonitis and respiratory failure.1 Fatal adverse reactions occurred in 7 (2%) patients, and included hepatic toxicity, acute renal failure, sepsis, pneumonitis, diarrhea with hypokalemia and massive hemoptysis in the setting of thrombocytopenia.1 The most common (>20%) adverse reactions were fatigue (49%), musculoskeletal pain (39%), nausea (32%), diarrhea (31%), rash (30%), decreased appetite (28%), constipation (21%) and pruritus (21%).1

About Lung Cancer

Lung cancer is the leading cause of cancer death in the United States.12 The two main types of lung cancer are non-small cell and small cell.13 Non-small cell lung cancer is one of the most common types of lung cancer, and accounts for approximately 84% of diagnoses.13 Survival rates vary depending on the stage and type of the cancer when diagnosed.12

INDICATIONS

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. For this indication, OPDIVO 3 mg/kg is administered every 2 weeks with YERVOY 1 mg/kg every 6 weeks.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Please see U.S. Full Prescribing Information for OPDIVO and YERVOY, including Boxed WARNING regarding immune-mediated adverse reactions for YERVOY.

Bristol Myers Squibb: Advancing Cancer Research

At Bristol Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase patients quality of life, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and Immuno-Oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering potential new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.

About Bristol Myers Squibbs Patient Access Support

Bristol Myers Squibb remains committed to providing assistance so that cancer patients who need our medicines can access them and expedite time to therapy.

BMS Access Support, the Bristol Myers Squibb patient access and reimbursement program, is designed to help appropriate patients initiate and maintain access to BMS medicines during their treatment journey. BMS Access Support offers benefit investigation, prior authorization assistance, as well as co-pay assistance for eligible, commercially insured patients. More information about our access and reimbursement support can be obtained by calling BMS Access Support at 1-800-861-0048 or by visiting http://www.bmsaccesssupport.com.

About the Bristol Myers Squibb and Ono Pharmaceutical Collaboration

In 2011, through a collaboration agreement with Ono Pharmaceutical Co., Bristol Myers Squibb expanded its territorial rights to develop and commercialize Opdivo globally, except in Japan, South Korea and Taiwan, where Ono had retained all rights to the compound at the time. On July 23, 2014, Ono and Bristol Myers Squibb further expanded the companies strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for patients with cancer in Japan, South Korea and Taiwan.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

References

SOURCE: Bristol-Myers Squibb

See the rest here:
US Food and Drug Administration Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of...

TheGlobal Canavan Disease Marketwas estimated to be valued at USD XX million in 2019 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026.

Canavan disease is an autosomal recessive degenerative disorder that causes progressive damage to nerve cells in the brain. The market is primarily driven by increasing prevalence of life threatening cerebral diseases. However, lack of awareness and lack of skilled neurologist might impede the market growth.

Get Sample Copy of this Report @https://www.orianresearch.com/request-sample/1040619

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The key players profiled in the market include:Johnson & Johnson, GlaxoSmithKline plc., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Amgen, Inc., Turing Pharmaceuticals AG, Pfizer Inc., Aspa Therapeutics and BridgeBio

Key Benefits of the Report:

Global Canavan DiseaseMarket is spread across 121 pages

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/1040619

On the basis of types, the market is split into:

Based on applications, the market is divided into:

Moreover, the market is classified based on regions and countries as follows:

Order a Copy of Global Canavan Disease Market Report @https://www.orianresearch.com/checkout/1040619

Target Audience:

Table Of Content

1 Introduction

2 Research Methodology

3 Executive Summary

4 Global Canavan Disease Market Overview

5 Global Canavan Disease Market, by Product Type

6 Global Canavan Disease Market, by Application

7 Global Canavan Disease Market by Region

8 Competitive Landscape

9 Company Profiles

10 Key Insights

Customization Service of the Report:Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Contact Us:Ruwin MendezVice President Global Sales & Partner RelationsOrian Research ConsultantsUS +1 (415) 830-3727 | UK +44 020 8144-71-27Email:[emailprotected]Website: http://www.orianresearch.com/

About UsOrian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Read this article:
COVID-19 Impact on Global Canavan Disease Market 2020: Industry Share, Size, Applications, Top Key Players and Forecast Research to 2026 - 3rd Watch...

Magarpatta SEZ, Pune, ReportsnReportsprovides in depth study ofHemophilia Gene Therapy Marketusing SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organisation. The Hemophilia Gene Therapy Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organisation such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organisation.

The global Hemophilia Gene Therapy Market is expected to witness a promising growth in the next few years. The rising level of competition among the leading players and the rising focus on the development of new products are likely to offer promising growth opportunities throughout the forecast period. The research study on the global Hemophilia Gene Therapy Market offers a detailed overview, highlighting the key aspects that are expected to enhance the growth of the market in the near future. The key segmentation and the competitive landscape of the market have also been mentioned at length in the research study.

GetFree Sample PDF Copy of Hemophilia Gene Therapy Market with Figures, Graphs and Tocs:https://www.reportsnreports.com/contacts/requestsample.aspx?name=2840557

The global Hemophilia Gene Therapy Market is highly fragmented. Small market players operating at regional and local levels are challenging the market shares of the leading players (on the basis of cost differentiation and technical support services). In order to maintain their market shares, leading players are continuously developing new technologies and upgrading their existing products and services to enhance their product portfolios. Increasing competition is expected to drive innovation in the market, thereby helping the industry to overcome existing challenges in the field of healthcare mobility and at the same time address user compliance issues and unmet needs of the market.

Analysis on Strategies of Leading Players: Market players can use this evaluation to gain competitive advantage over their competition inside the global Hemophilia Gene Therapy Market.

Summary

Market OverviewThe global Hemophilia Gene Therapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.The Hemophilia Gene Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentationHemophilia Gene Therapy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.By Type, Hemophilia Gene Therapy market has been segmented into Hemophilia A, Hemophilia B, etc.By Application, Hemophilia Gene Therapy has been segmented into Hemophilia A Gene Therapy, Hemophilia B Gene Therapy, etc.

Regions and Countries Level AnalysisRegional analysis is another highly comprehensive part of the research and analysis study of the global Hemophilia Gene Therapy market presented in the report. This section sheds light on the sales growth of different regional and country-level Hemophilia Gene Therapy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Hemophilia Gene Therapy market.The report offers in-depth assessment of the growth and other aspects of the Hemophilia Gene Therapy market in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Hemophilia Gene Therapy markets such as North America, Europe, Asia-Pacific, South America and Middle East & Africa.

Competitive Landscape and Hemophilia Gene Therapy Market Share AnalysisHemophilia Gene Therapy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Hemophilia Gene Therapy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Hemophilia Gene Therapy sales, revenue and market share for each player covered in this report.The major players covered in Hemophilia Gene Therapy are: Spark Therapeutics, Freeline Therapeutics, Sangamo Therapeutics, Ultragenyx, uniQure, Shire PLC, BioMarin, Bioverativ, etc. Among other players domestic and global, Hemophilia Gene Therapy market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The Hemophilia Gene Therapy Market industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

Enquire More About Hemophilia Gene Therapy Market:https://www.reportsnreports.com/contacts/discount.aspx?name=2840557

This report studies the Hemophilia Gene Therapy Marketstatus and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Hemophilia Gene Therapy Marketby product type and applications/end industries. These details further contain a basic summary of the company, merchant profile, and the product range of the company in question. The report analyzes data regarding the proceeds accrued, product sales, gross margins, price patterns, and news updates relating to the company.

Other than the aforementioned parameters which Hemophilia Gene Therapy Market report focuses on, another imperative objective of the report is to present the Hemophilia Gene Therapy Market development across the globe especially in North America, Europe, China, Japan, Southeast Asia, India and Central and South America. In the report, the market has been categorized into manufacturers, type, application and regions.

Avail 20% offer on Full Report Using Coupon Code Available on website @https://www.reportsnreports.com/purchase.aspx?name=2840557

The report helps to identify the main Hemophilia Gene Therapy Marketplayers. It assists in analyzing Hemophilia Gene Therapy Market competitive environment, including company overview, company total revenue, market opportunities, value, production sites and facilities, SWOT analysis, product details. The study also reveals the sales, revenue and market share for each market player included in this report for the period of 2015-2020. It also helps to ascertain the growth drivers and future prospects for the forecast timeline.

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Hemophilia Gene Therapy Marketforecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, growth drivers of by analyzing the historical overall data of the considered market segments.

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

We provide 24/7 online and offline support to our customers.

E-mail: [emailprotected]

Phone: +1 888 391 5441

Read the original post:
Hemophilia Gene Therapy Market 2020 by Global Industry Trends, Sales Revenue, Industry Growth, Development Status, Top Leaders, Future Plans and...

Global Viral Vector & Plasmid DNA Manufacturing Market Report is a finished appraisal of current market Status, Opportunities, Trends, and individual pieces of the pie of the absolute most conspicuous players in this scene. The investigation contains mindful experiences, realities, chronicled information, and factually bolstered and industry-approved market information. This examination additionally investigates Business models, Key techniques, and Growth openings in the up and coming years.

The catchphrase showcase report looks at the financial status and anticipation of worldwide and significant areas, in the possibility all things considered, types and end-client application/ventures; this report analyzes the most striking players in major and worldwide locales, likewise partitions the Viral Vector & Plasmid DNA Manufacturing advertise by portions and applications/end organizations.

Solicitation for Sample Copy @ http://www.researchreportsinc.com/report-sample/821488

Significant Key Vendors:-

Worldwide Viral Vector & Plasmid DNA Manufacturing Market bits of knowledge spread qualities, development, and size, division, provincial retreats, serious scene, pieces of the pie, patterns, and plans. The qualities part of this catchphrase report characterizes and clarifies the development. The Viral Vector & Plasmid DNA Manufacturing showcase size office gives industry income, covering the verifiable development of this and foreseeing the since quite a while ago run. Viral Vector & Plasmid DNA Manufacturing Drivers and limitations with the factors influencing the development of this market. The division isolate the fundamental catchphrase sub-businesses that structure the market.

Types are separated into:

Applications are separated into:

Noteworthy areas shrouded in this report:

North America, China, Rest of Asia-Pacific, UK, Europe, Central South America, Middle East Africa

Get Discount on this report @ http://www.researchreportsinc.com/check-discount/821488

The Viral Vector & Plasmid DNA Manufacturing investigation consolidates authentic information from 2014 to 2019 and forecasts until 2025 assisting with making the reports an important asset for industry administrators, advancement, item and project leads, counselors, experts, and various individuals attempting to discover essential catchphrase industry information in promptly available records with unmistakably showed tables and diagrams.

Significant Points Covered In The Report:

Connect With Us:

Name: David

Email: [emailprotected]

Website: http://www.researchreportsinc.com

Telephone: UK: +4403308087757 USA: +18554192424

Originally posted here:
Impact COVID-19 on Viral Vector & Plasmid DNA Manufacturing Market Along with Major Market Players | Merck, uniQure, The Cell and Gene Therapy...

Global Cell and Gene Therapy Market

The Global Cell and Gene Therapy Market report consists of the latest discoveries and technological advancements recorded in the industry, along with an analysis of the factors and their effect on the markets future development. The report focuses on the current businesses and the present-day headways, and the future growth prospects for the Cell and Gene Therapy market.

This report covers the current COVID-19 effects on the economy. This outbreak has brought along drastic changes in world economic situations. The current scenario of the ever-evolving business sector and present and future appraisal of the effects are covered in the report as well.

The Global Cell and Gene Therapy market size will reach XX Million USD by 2027, from XX Million USD in 2019, at a CAGR of XX% during the forecast period.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/122295

The global Cell and Gene Therapy marketreport gives a 360 approach for a holistic understanding of the market scenario. It relies on authentically-sourced information and an industry-wide analysis to predict the future growth of the sector. The study gives a comprehensive assessment of the global Cell and Gene Therapy industry, along with market segmentation, product types, applications, and value chain.

The study also delivers accurate insights into the market in the forecast duration and other key facts and figures pertaining to the global Cell and Gene Therapy market.

Leading Cell and Gene Therapy manufacturers/companies operating at both regional and global levels:

Amgen Inc., bluebird bio, Inc. Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cell Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Organogenesis Holdings Inc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, and ViroMed Co., Ltd., among others.

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research Objective:

Our panel of trade analysts has taken immense efforts in doing this group action in order to produce relevant and reliable primary & secondary data regarding the global Cell and Gene Therapy market. Also, the report delivers inputs from the trade consultants that will help the key players in saving their time from the internal analysis. Readers of this report are going to be profited with the inferences delivered in the report. The report gives an in-depth and extensive analysis of the Cell and Gene Therapy market.

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketexpertz.com/checkout-form/122295

Cell and Gene Therapy Market has maintained a steady growth rate in the past decade and is predicted to grow at a higher growth rate during the forecast period. The analysis offers an industry-wide evaluation of the market by looking at vital aspects like growth trends, drivers, constraints, opinions of industry experts, facts and figures, historical information, and statistically-backed and trade valid market information to predict the future market growth.

The Global Cell and Gene Therapy Market is segmented:

In market segmentation by types of Cell and Gene Therapy, the report covers-

ell and gene therapy manufacturing landscape:

upstream manufacturing, and downstream manufacturing.

product landscape:

therapeutic market and pipeline analysis.

In market segmentation by applications of the Cell and Gene Therapy, the report covers the following uses-

oncology, hematology, cardiovascular, ophthalmology, neurology

This Cell and Gene Therapy report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Get Your Copy at Incredible [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/122295

Cell and Gene Therapy Market Regional Analysis:

Geographically, the Cell and Gene Therapy market is segmented across the following regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa.

Key Coverage of Report:

Have a query? Ask our Expert @ https://www.marketexpertz.com/customization-form/122295

Key insights of the report:

Access the Entire Report with TOC, Tables and Figures, and details of Prominent [emailprotected] https://www.marketexpertz.com/industry-overview/2020-global-cell-and-gene-therapy-market

In conclusion, the Global Cell and Gene Therapy Market report provides a detailed study of the market by taking into account leading companies, present market status, and historical data to for accurate market estimations, which will serve as an industry-wide database for both the established players and the new entrants in the market.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

Read the original post:
Cell and Gene Therapy Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By 2027 |...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants. The increasing prevalence of chronic diseases will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increasing prevalence of chronic diseases has been instrumental in driving the growth of the market.

Regenerative Medicine Market 2020-2024: Segmentation

Regenerative Medicine Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41171

Regenerative Medicine Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our regenerative medicine market report covers the following areas:

This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicine market growth during the next few years.

Regenerative Medicine Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the regenerative medicine market, including some of the vendors such as Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. Backed with competitive intelligence and benchmarking, our research reports on the regenerative medicine market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Regenerative Medicine Market 2020-2024: Key Highlights

Table Of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Originally posted here:
Research Report with COVID-19 Forecasts - Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth |...

Facts & Factors Market Research, leading market research and consulting firm added the latest industry outlook report on Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 20202026 consisting of 190+ pages during the forecast period 2020 to 2026 and the Cancer Gene Therapy Market Market report offers comprehensive research updates and information related to market growth, demand, and opportunities in the Cancer Gene Therapy Market Market.

TheCancer Gene Therapy Market marketreport analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire Cancer Gene Therapy Market market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Billion) from FY 2016 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Cancer Gene Therapy Market industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Request an Exclusive Free Sample Report of Cancer Gene Therapy Market Market:https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

Our Every Readily Available Free Sample Includes:

Some of Top Market Players Analysis Included in this Report:

The Market Player Analysis based on some of below Factors:

Impact of COVID-19 Pandemic on Cancer Gene Therapy Market Market

The COVID-19 outbreak has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The decrease in the overall market growth due to COVID-19 is also affecting the growth of the Cancer Gene Therapy Market market owing to the shutting down of factories, obstacles in supply chain, and a downturn in the world economy.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Gene Therapy Market market by product type, application, key manufacturers and key regions and countries. In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Request Customized Copy of Report @https://www.fnfresearch.com/customization/cancer-gene-therapy-market-by-type-ex-vivo-898

(We customize your report according to your research need. Ask our sales team for report customization).

Available Customization Options:

The Cancer Gene Therapy Market Market can be customized to the country level or any other market segment. Besides this, Report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

The report provides the complete view of the Cancer Gene Therapy Market market and encompasses a detailed type portfolio and strategic developments of key vendors. To know the competitive landscape of the Cancer Gene Therapy Market market, an analysis of Porters five forces model is done. The study cover market attractiveness analysis, in which type, source type, and application segments are specialized based on the market size, growth rate, and attractiveness.

The report study further includes an in-depth analysis of industry players market shares and provides an overview of leading players market position in the Cancer Gene Therapy Market sector. Key strategic developments in the Cancer Gene Therapy Market market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the Cancer Gene Therapy Market market are appropriately highlighted in the report.

Make an Enquiry Before Purchase this Report @https://www.fnfresearch.com/inquiry/cancer-gene-therapy-market-by-type-ex-vivo-898

To Know More about Discount on Specific Report, Kindly Mail us at [[emailprotected]]with Your requirement. We will send you a quote and discount offer, if available.

KEY REPORT POINTERS & HIGHLIGHTS:

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,

8 Century Avenue, Shanghai,

Postal 200120, China

Tel: +8621 80360450

E-Mail:[emailprotected]

Web:https://www.fnfresearch.com

Excerpt from:
Cancer Gene Therapy Market Size & Trends 2020 Research With COVID-19 Impact Analysis & Insights Report Forecast to 2026 - 3rd Watch News

SEATTLE, May 25, 2020 (GLOBE NEWSWIRE) -- Various lesions or diseases of the somatosensory system may lead to neuropathic pain. Nerve blockage and pharmacological remedies are used in the treatment and management of neuropathic pain.

The global neuropathic pain market is estimated to account for US$ 9,862.3 Mn in terms of value by the end of 2027.

Market Drivers:

High prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.

Market Opportunities:

R&D in neuropathic pain is expected to offer lucrative growth opportunities for players in the market. For instance, in May 2020, researchers from University Medical Center Hamburg-Eppendorf and other prominent universities in Germany reported that loss of C-fiber may lead to neuropathic pain in Schwannomatosis, a form of neurofibromatosis caused due to the occurrence of multiple schwannomas, tumors that develops from the Schwann cells.

Moreover, adoption of nanoparticles in therapies is also expected to aid in growth of the global neuropathic pain market. For instance, in May 2020, researchers from Chungnam National University Hospital, South Korea, reported that poly(D,L-lactic-co-glycolic acid)-encapsulated CX3CR1 small interfering RNAs nanoparticles may aid in the treatment of neuropathic pain.

Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3656

Key Takeaways:

The global neuropathic pain market was valued at US$ 6,313.4 Mn in 2019 and is forecast to reach US$ 9,862.3 Mn by 2027 at a CAGR of 5.6% between 2020 and 2027. Increasing prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period.

Anticonvulsants segment held dominant position in the global neuropathic pain market in 2019, accounting for 40.8% share in terms of value. Development of new drugs for the treatment of neuropathic pain is expected to drive the segment growth.

Diabetic neuropathy segment held dominant position in the global neuropathic pain market in 2019, accounting for 46.4% share in terms of value, followed by Chemotherapy-induced peripheral neuropathy and others, respectively. Increasing prevalence of diabetic neuropathy in developing economies is expected to assist the growth of the segment during the forecast period.

Market Trends:

Various studies are focused on developing alternatives to drugs in the treatment of neuropathic pain. For instance, in March 2020, researchers at the Autonomous University of the State of Hidalgo, Mexico, reported that pomegranate and secondary metabolites can be effective in the treatment of inflammatory, nociceptive, and neuropathic pain.

The market is witnessing adoption of combination therapies as an effective approach in the treatment of neuropathic pain. For instance, in March 2020, researchers from Universitat Autnoma de Barcelona, Spain, reported that NeuroHeal a combination of two repurposed drugs: Acamprosate and Ribavirin reduces the appearance of neuropathic pain in peripheral nerve injury.

Competitive Landscape:

Major players operating in the global neuropathic pain market include, Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., CODA Biotherapeutics, Inc., Eliy Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Sqibb, Baxter Healthcare Corporation, Neuroheal Biomedicals, S.L., and Depomed, Inc.

Key Developments:

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in May 2020, CODA Biotherapeutics, Inc. collaborated with the Facial Pain Research Foundation for R&D of new therapies for trigeminal neuralgia and related neuropathic pain using CODAs chemogenetic gene therapy platform.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3656

Taxonomy (Scope, segments)

Follow this link:
Neuropathic Pain Market to reach US$ 9,862.3 Million globally by 2027 Coherent Market Insights - GlobeNewswire

As the number of U.S. spinal muscular atrophy (SMA) patients Zolgensma treats each quarter stabilizes, Novartis is counting on a set of inflection points for future growth. Now, it has one.

After a manufacturing-related delay, Novartis has won conditional approval in the EU for the one-time gene therapy to treat patients with a clinical diagnosis of SMA type 1 and others with up to three copies of the SMN2 backup gene, the company said Monday.

Zolgensmas EU label is different from the U.S. version. While its approved by the FDA to treat children less than 2 years of age, the EMA allows it in babies and young children who weigh up to 21 kilograms. According to a Pediatric Neuromuscular Clinical Research natural history study of SMA, almost all patients under the age of 5 will be under 21 kg.

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

The number of SMN2 genes determines the severity of the disease, with SMA type 1 the most severe form. The U.S. approval is for all SMA types, but the EU nod leaves out a small proportion of patients who could develop mild, late-onset type 3 or type 4 SMA. Patients with type 3 SMA, sometimes called Kugelberg-Welander disease, may have up to four copies of SMN2.

The difference could havemixed effectson Zolgensmas opportunity in the two territories. For existing patients already on Biogens Spinraza, Zolgensma could steal share from older patients in the EU. But for new patients, the FDA label enables the Novartis drug to reach more patients if diagnosis through newborn screening is widely adopted and patients are treated early.

Zolgensma has reached a steady state where it treats about 100 patients per quarter in the U.S., Novartis CEO Vas Narasimhan recently told investors. That translated into $170 million sales in the first quarter, a slight quarter-over-quarterdecline due to COVID-19. The companys expecting approvals in new countriesand new indications to be inflection points that will eventually propel the drug to blockbuster sales.

RELATED:The top 10 drug launches since 2017 | 7. Zolgensma

It had the first point in March with a Japanese nod, also for patients under 2 years old. Last week, the Japanese government approved Zolgensmas price at 167 million yen ($1.55 million), lower than its U.S. list price of $2.12 million.

In Europe, final pricing and reimbursement decisions will be determined at the local level, a spokesperson at Novartis AveXis gene therapy unit told FiercePharma. Cumulative healthcare costs per SMA patient are estimated at between 2.5 million to 4 million over the first 10 years, the company said.

Novartis said its working with European countries local regulators on an access program called Day One. Its designed to provide fast access to Zolgensma even before national pricing and reimbursement agreements are in place, a process that sometimes takes years. The program offers several options such as deferred payments and installment over years as well as outcomes-based rebates. The drug has been made available in France under the countrys Temporary Authorization for Use pathway, and access is expected shortly in Germany, the Swiss drugmaker said.

Beyond the already-approved intravenous version, Novartis is developing a formulation that delivers Zolgensma through an injection into the spinal canal so that it can reach older patients up to 5 years of age in the U.S. Its working with the FDA to resolve a partial clinical hold slapped on the high dose of the intrathecal formulation before it can file for an approval.

Currently, AveXis makes Zolgensma at its site in Libertyville, Illinois. It also has plants in Durham, North Carolina, and Longmont, Colorado. The latter two are expected to be licensed in 2021, the company spokesperson said, adding that it has no plans for a manufacturing facility in the EU at this point.

Read the rest here:
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy - FiercePharma

COVID-19 Impact Analysis of Hemophilia Gene Therapy Market

[Los Angeles], [United States], May 2020, The Hemophilia Gene Therapy Market research report includes an in-sight study of the key [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026] market prominent players along with the company profiles and planning adopted by them. This helps the buyer of the Hemophilia Gene Therapy report to gain a clear view of the competitive landscape and accordingly plan Hemophilia Gene Therapy market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Hemophilia Gene Therapy specifications, and company profiles. The Hemophilia Gene Therapy study is segmented by Module Type, Test Type, And Region.

The market size section gives the Hemophilia Gene Therapy market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Hemophilia Gene Therapy industry over a defined period.

Download Full PDF Sample Copy of Report: https://www.qyresearch.com/sample-form/form/1436276/global-hemophilia-gene-therapy-market

Key Manufacturers of Hemophilia Gene Therapy Market include: Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics

The research covers the current market size of the [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026]and its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc., by product type Hemophilia A, Hemophilia B, by applications Hemophilia A Gene Therapy, Hemophilia B Gene Therapy in overall market. The in-depth information by segments of Hemophilia Gene Therapymarket helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026].

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026]. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Read Detailed Index of full Research Study: https://www.qyresearch.com/index/detail/1436276/global-hemophilia-gene-therapy-market

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Hemophilia Gene Therapyin these regions, from 2012 to 2022 (forecast), covering

Please Check below Chapters to display the [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026].

There are 15 Chapters to display the [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026].

Chapter 1, to describe Definition, Specifications and Classification of Hemophilia Gene Therapy, Applications of Hemophilia Gene Therapy, Market Segment by Regions;

Chapter 2, To analyse the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Hemophilia Gene Therapy, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics), Sales Analysis (Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics), Sales Price Analysis (Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics);

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc., Hemophilia Gene Therapy Segment Market Analysis (Hemophilia A, Hemophilia B);

Chapter 7 and 8, to analyse the Hemophilia Gene Therapy Segment Market Analysis (Hemophilia A Gene Therapy, Hemophilia B Gene Therapy) Major Manufacturers Analysis of Hemophilia Gene Therapy;

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type [Type], Market Trend [Hemophilia A Gene Therapy, Hemophilia B Gene Therapy];

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyse the Consumers Analysis of Hemophilia Gene Therapy;

Chapter 12, to describe Hemophilia Gene Therapy Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Hemophilia Gene Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

See the rest here:
Global Hemophilia Gene Therapy Market 2020 Business Outlook with COVID-19 Scenario Analysis and Forecast 2026 - Weekly Wall

Global Cancer Gene Therapy market report studies the market situation and outlook represents the global Cancer Gene Therapy market size (value and volume) and Share by companies, type, application, and region. The widespread Global Cancer Gene Therapy trends and opportunities are also taken into consideration in Cancer Gene Therapy industry study Cancer Gene Therapy Market report focus on the following section is to analyze the Cancer Gene Therapy industry by adoption among various segments; the primary product types covered under the scope of the report.

This Cancer Gene Therapy market report is a complete analysis of the Cancer Gene Therapy market based on primary and secondary in-depth analysis. The scope of the Cancer Gene Therapy market report includes global and regional sales, product consumption in terms of volume, and value. The global Cancer Gene Therapy market report provides an estimate of revenue, CAGR, and aggregate revenue. The collected knowledge about Cancer Gene Therapy global business is represented in the figures, tables, pie charts, and graphs.

Get FREE Research Sample By Using Corporate Mail ID @https://market.us/report/cancer-gene-therapy-market/request-sample

MANUFACTURERScovered in this Cancer Gene Therapy market report:

Sun-Maid, Arimex, Olam International, Sunbeam Foods, Diamond Foods, Archer Daniels Midland, Kanegrade, Graceland, Hines Nut Company, H.B.S. Foods

On the basis of product each TYPES primarily split into:

Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

On the basis of product each APPLICATIONS primarily split into:

Hospitals, Diagnostics Centers, Research Institutes

Market Primarily Focusing On Cancer Gene Therapy Market:

South America & including countries

The Middle East and Africa

North America

Europe

Asia-Pacific & included countries.

Customized Research ReportUsing Corporate Email Id @ https://market.us/report/cancer-gene-therapy-market/#inquiry

Global Cancer Gene Therapy Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global Cancer Gene Therapy market and also about each type from 2015 to 2029. This section mentions the volume of sales by region from 2015 to 2029. Pricing analysis is included in the report according to each type from the year 2015 to 2029, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2029.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing Cancer Gene Therapy market. Additionally, insights into market experts opinions have been taken to understand the market better.

Global Cancer Gene Therapy Market: Segment Analysis

The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2029. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the Cancer Gene Therapy market growth.

Global Cancer Gene Therapy Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Cancer Gene Therapy report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2029. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Cancer Gene Therapy Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the Cancer Gene Therapy market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

PurchaseWhole Research Analysis @ https://market.us/purchase-report/?report_id=54259

CONTACT US :

Mr. Benni JohnsonMarket.us (Powered By Prudour Pvt. Ltd.)

Email:[emailprotected]

Address:

420 Lexington Avenue,Suite 300 New York City,NY 10170, United StatesTel: +1 718 618 4351

Website:https://market.us

More RelatedReports Here:

Expanded Polytetrafluoroethylene Market with Pertinent Opportunities by 2029 | GORE and Guarnitex

World News For Active Pharmaceutical Ingredients Market | Increased Research and Development Activities Boosts by 2020-2029 | BioSpace

Specific Equipment Reports @https://chemicalmarketreports.com/

See the original post:
Impact of COVID-19 on Global Cancer Gene Therapy Market Research Segment (2020-2029) || Sun-Maid, Arimex, Olam International - Cole of Duty

XconomyNational

COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets.

Gene therapy company Generation Bio, vaccines developer Vaxcyte, and cancer diagnostics maker Burning Rock Biotech each filed IPO paperwork just ahead of the Memorial Day weekend. The filings come as an index of the largest and most liquid IPOs of the past two years reached an all-time high, according to Renaissance Capital. The IPO research firm says the indexs rise was led by Moderna (NASDAQ: MRNA), the Cambridge, MA-based biotech that this week released preliminary Phase 1 data for its experimental COVID-19 vaccine.

Investors are betting that new technologies and services are best suited for the post-pandemic world, Renaissance says.

Heres a look at the three new additions to the biotech IPO queue.

GENERATION BIO EYES NEXT-GEN GENE THERAPIES

Generation Bio aims to improve upon gene therapy with an alternative to the engineered viruses currently used to ferry these therapies into cells. Viral delivery has limitations that include safety risks and a relatively small genetic payload capacity, the Cambridge-based company says in its filing. Furthermore, if patients dont already have antibodies to the viruses, they develop them after their first dose, which means patients cant receive additional doses if the initial one doesnt work as expected or stops working over time. Gene therapies that employ viral delivery are also expensive to manufacture.

Instead of a virus as its delivery vehicle, Generation Bio uses a lipid nanoparticle (LNP). The LNP encapsulates its genetic payload, a DNA construct called closed-ended DNA. This approach permits an individualized approach to treatment as a patient can be redosed until reaching the level needed for effective treatment, the company says. The technology also has a greater payload capacity and its less expensive to manufacture at scale compared to viral gene therapies. Those differences will enable delivery of gene therapies to more types of tissue, which in turn will allow for the treatment of a broader range of diseases spanning more patients, Generation Bio says.

Generation Bios initial focus is developing gene therapies targeting diseases of the liver and the eye. The most advanced liver programs are for phenylketonuria (PKU), an inherited metabolic disorder, and hemophilia type A, the most common form of the bleeding disorder. For the eye, Generation Bio is developing a gene therapy for an inherited form of vision loss called Leber congenital amaurosis 10 (LCA10) and for Stargardt disease, which is a form of macular degeneration.

Those programs trail other experimental gene therapies that are currently in clinical testing. Pfizer (NYSE: PFE) is developing a hemophila A gene therapy that came from the labs of partner Sangamo Therapeutics (NASDAQ: SGMO). BioMarin Pharmaceutical (NASDASQ: BMRN) is testing gene therapies for hemophilia A and PKU. In LCA10,Editas Medicine (NASDAQ: EDIT) is developing a gene therapy under a partnership with Allergan, now a subsidiary of AbbVie (NYSE: ABBV). That therapeutic candidate uses the CRISPR gene-editing technology to correct the faulty gene inside the patient. All of these experimental gene therapies use adeno-associated viruses to reach their targets.

Generation Bio has raised more than $227 million, most recently a $110 million Series C financing in January. That funding round added crossover investors, whose involvement is viewed as an indication a company is preparing for an IPO. CEO Geoff McDonough acknowledged as much at the time, telling Xconomy he expected to take the company public in advance of beginning clinical trials. Other rare diseases that the company is exploring include Wilsons disease and Gaucher disease.

In its filing, Generation Bio set a preliminary $125 million target for its IPO. The company has applied for a Nasdaq listing under the stock symbol GBIO. At the end of the first quarter of this year, Generation Bio reported having $104.5 million in cash. The company says it plans to use the IPO proceeds to continue R&D, including the preclinical work to support an application to start clinical testing of one of its liver disease gene therapies.

Generation Bios largest shareholders are Jason Rhodes, the companys chairman and founding CEO, and Atlas Venture. Each holds a 37 percent pre-IPO stake, according to the filing. Fidelity Investment owns 14.9 percent of the company, followed by funds advised by T. Rowe Price, which hold 8.9 percent.

VAXCYTE SETS SIGHTS ON TOPPING A PFIZER VACCINE

Vaxcyte is the new name for SutroVax, which changed its moniker this week. The Foster City, CA-based company spun out of Sutro Biopharma, and it develops vaccines using technology licensed from its former parent. The company says in its IPO filing that its cell-free protein synthesis technology enables it to design protein carriers and antigensa vaccines key componentsthat are better than what can be produced using conventional vaccine technologies.

Pneumococcal bacteria, which can cause pneumonia and meningitis, are Vaxcytes first target. The top pneumococcal vaccine, a Pfizer (NYSE: PFE) product called Prevnar 13, is a blockbuster seller that protects against 13 of the more than 90 pneumococcal strains. Vaxcytes preclinical vaccine candidate, VAX-24, is being developed to address 24 strains.

The IPO filing comes two months after Vaxyte closed a $110 million Series D round that added crossover investors. The company says in the filing that it has raised about $282 million cumulatively. As of March 31, Vaxcytes cash holdings totaled $154.7 million. The companys largest shareholders include Abingworth Bioventures, Longitude Capial Management, and Roche Finance, though the percentages of those stakes were not disclosed.

Vaxcyte says it plans to apply for a Nasdaq listing under the stock symbol PCVX. The vaccine developer set a preliminary $100 million goal; proceeds will be used to complete preclinical development and advance VAX-24 into human testing. The cash will also finance manufacturing, as well as continued development of other vaccine candidates.

BURNING ROCK BIOTECH BLAZES A PATH TO NASDAQ

Burning Rock Biotech is based in China, where it sells next-generation sequencing products that help physicians select cancer treatments for their patients. Now its seeking a Nasdaq listing that will give US investors a chance to grab a stake.

The company says in its filing that it offers 13 tests spanning solid tumors including cancers of the lung, prostate, and breast, as well as blood cancers. In addition helping physicians treat cancer patients, Burning Rock says its products support clinical trials conducted by large pharmaceutical companies, including AstraZeneca (NYSE: AZN), Bayer, and Johnson & Johnson (NYSE: JNJ). The companys central laboratory processes biopsy samples from hospital patients as well as from its pharmaceutical partners. The central lab business is the companys largest business segment.

Burning Rock reported $53.9 million in 2019 revenue. For the first quarter of 2020, revenue was $9.5 million. The company set a preliminary $100 million goal for its IPO, and says it plans to apply for a Nasdaq listing under the stock symbol BNR. According to the filing, Burning Rock expects to use the IPO cash for research and development of early cancer detection technologies, as well as for seeking approvals in China for additional cancer therapy selection products.

Image: iStock/peterschreiber.media

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com.

Originally posted here:
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq - Xconomy

Others at the center, which coordinates research at eight universities, are reviewing past work on drugs that showed potential against the SARS epidemic in 2002 and the MERS outbreak in 2012. Both diseases are also caused by coronaviruses.

At some point, though, scientists at the center and across the country will need to focus on future threats and break new ground.

You can make a lot of movement fast, based on what you know, Satchell said. But at some point, you hit a wall where you have to discover new things.

Andy Mesecar needs a weekend off.

An expert in biochemistry and gene therapy, hes worked seven-day weeks for the last few months, racing to find a drug for patients with COVID-19 while teaching at Purdue University and submitting daily reports to the National Institutes of Health. The center at Northwestern has funded his work since 2018.

Mesecar has a manuscript under review in a scientific journal on how a drug approved to treat hepatitis C could be modified to potentially treat COVID-19. His lab is one of the leading centers studying coronaviruses, and he and his team have dedicated nearly two decades to the research. But that was still not enough to rapidly create an effective therapy specific to COVID-19.

With a background in biochemistry and structural biology, Mesecar started out as an assistant professor at the University of Chicago, studying enzymes that could fight cancer. He got into infectious diseases after the anthrax attacks in the weeks after 9/11. Then, he pivoted to studying enzymes that could be used against SARS when it surfaced in November 2002.

Originally posted here:
Everything we did was to predict the next outbreak. Yet scientists werent prepared for COVID-19. Why? - Longview Daily News

Latest Market Research Report onGene Therapies for Cancer Treatment Market size | Industry Segment by Applications (Cancer Research Centers, Diagnostic Laboratories, Cancer Hospitals and Others), by Type (Somatic Cell Gene Therapy (SCGT) and Germline Gene Therapy (GGT), Regional Outlook, Market Demand, Latest Trends, Gene Therapies for Cancer Treatment Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

Gene Therapies for Cancer Treatment Market Report encompasses market attributes, size, growth forecast, segmentation, regional classifications, competitive landscape, Gene Therapies for Cancer Treatment market shares, trends and tactics of Gene Therapies for Cancer Treatment market. Gene Therapies for Cancer Treatment Marketreport highlights key dynamics of Global Gene Therapies for Cancer TreatmentIndustry sector. The potential of the Gene Therapies for Cancer TreatmentMarket has been investigated along with the key challenges. The current Gene Therapies for Cancer TreatmentMarket scenario and prospects of the sector has also been studied.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/18524

As per the report, the Gene Therapies for Cancer Treatment market has been further divided into crucial segments. A brief of the industry with regards to the market size in terms of the volume and renumeration aspects, as well as the current picture of Gene Therapies for Cancer Treatment market has been included in the report. The research speaks about the information related to the geographical segment of this vertical along with the firms that have achieved a significant position across the marketplace.

Gene Therapies for Cancer Treatment Market Report covers themanufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc.,these data help the consumer know about the competitors better. This report also covers all theregions and countries of the world, which shows a regional development status, includingGene Therapies for Cancer Treatment market size, volume and value, as well as price data.

Report Scope:

Gene Therapies for Cancer Treatment market competition by top Manufacturers:

Gene Therapies for Cancer Treatment Market Outlook by Applications:

Gene Therapies for Cancer Treatment Market Statistics by Types:

An Outline of Gene Therapies for Cancer Treatment Market report covers:

This report for Gene Therapies for Cancer Treatment Market discovers diverse topics such as regional market scope, product market various applications, market size according to specific product, sales and revenue by region, manufacturing cost analysis, Industrial Chain, Market Effect Factors Analysis, market size forecast, and more.

A vital point from TOC of Gene Therapies for Cancer Treatment Market analysis report are as below:

Executive Summary

Market Drivers, Challenges and Trends

Marketing, Distributors and Customer

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/18524

See the rest here:
Gene Therapies for Cancer Treatment Industry Size 2019, Market Opportunities, Share Analysis up to 2025 - ZZReport

Stem Cell Manufacturing Marketis expected to reach USD 16.51 Billion by 2025, from USD 10.28 Billion in 2017 growing at a CAGR of 6.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Get Sample Report PDF | @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-market

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Major Market competitors/players: Global Stem Cell Manufacturing Market

Some of the major players operating in the stem cell manufacturing market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc, Osiris Therapeutics, Osiris Therapeutics, Vericel Corporation, AbbVie, American CryoStem, AM-Pharma, Anterogen.Co.,Ltd, Astellas Pharma, Bristol-Myers Squibb, Apceth Biopharma, Cellular Dynamics International, Rheacell, Takeda Pharmaceutical, Teva Pharmaceutical Industries Ltd. ViaCyte, VistaGen Therapeutics Inc, Translational Biosciences, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, among others.

Global Stem Cell manufacturing Market,By Application (Research Applicationsand Clinical Applicationsand Cell and Tissue Banking), By Product (Stem Cell Line, Instruments, Culture Media and Consumables), By End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Table of Contents:

Highlights of the Study

Inquire about this report from our experts @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market

Major Market Drivers:

Report Scope

Our purpose is to serve you, the most customised in-depth Market access data. Our plethora of titles, made us one of the most searched market research library across the globe. We work with the most esteemed Publishers around the globe who caters vast industries. We are quick and fragile, when it comes to your various queries, and we ensure our team cater your needs to the best of our abilities, we promise to stay by your side for both pre and post sales servicing, as we believe in long everlasting symbiotic relationship.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:[emailprotected]

View post:
COVID-19 UPDATE : STEM CELL MANUFACTURING MARKET 2020 FUTURE GROWTH WITH TOP PLAYERS THERMO FISHER SCIENTIFIC. MERCK GROUP, BECTON, DICKINSON AND...

The global Gene Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Gene Therapy market player in a comprehensive way. Further, the Gene Therapy market report emphasizes the adoption pattern of the Gene Therapy across various industries.

The Gene Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Gene Therapy market provides a birds eye view of the current proceeding within the Gene Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Gene Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2654974&source=atm

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Gene Therapy market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Gene Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy market.The following players are covered in this report:Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.AdvantageneGene Therapy Breakdown Data by TypeEx vivoIn VivoGene Therapy Breakdown Data by ApplicationCancerMonogenicInfectious diseaseCardiovascular diseaseOther

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2654974&source=atm

The Gene Therapy market report offers a plethora of insights which include:

The Gene Therapy market report answers important questions which include:

The Gene Therapy market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2654974&licType=S&source=atm

Why Choose Gene Therapy Market Report?

Gene Therapy Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Continue reading here:
Coronavirus threat to global Gene Therapy Market Size, Demand, Cost Structures, Latest trends, and Forecasts to 2025 - Cole of Duty

(MENAFN - iCrowdNewsWire) May 25, 2020

The hemophilia treatment market was valued at US$ 14,454.81 million in 2019 and is expected to grow at a CAGR of 15.9% from 2020 to 2027 to reach US$44,089.71 million by 2027.

Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The disease is widely treated with replacement therapy and gene therapy. The other treatment which is used is medication. However, there are ways to reduce the risk of the condition, which include regular exercise and others. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.

Get sample PDF Report @ https://www.theinsightpartners.com/sample/TIPRE00008241/

Some of the prominent players operating in hemophilia treatment market are, Bayer AG, Sanofi, F. Hoffmann-la Roche Ltd., Kedrion S.P.A., CSL Limited, Biotest AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, and Baxter International Inc. The market players are focused towards acquisitions with industry players in order to sustain their position in the market. For instance, in February 2020, Novo Nordisk launched an antihemophilic product namely Esperoct. This product is likely to reduce the effect of hemophilia in adults and children with hemophilia A.

The hemophilia treatment market by product is segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents, desmopressin. In 2019, the plasma derived coagulation factor concentrates segment held a largest market share of the hemophilia treatment market. This segment is also expected to dominate the market in 2027. The large share of plasma derived coagulation factor concentrates based hemophilia treatment can be attributed to various advantages offered by these hemophilia treatment, deep market penetration and variety of products offered by multiple players to suit diverse medical application. On the other hand, the recombinant coagulation factor concentrates segment is anticipated to witness the highest growth rate during the forecast period. Certain factors such as effectiveness of the hemophilia treatment in lesser time and better efficient blood clotting are expected to drive the segment growth.

The plasma derived coagulation factor concentrates based hemophilia treatment captured the largest share in the globalhemophilia treatment market. A wide variety of hemophilia treatment is available as adjunctive measures to improve hemophilia if residual bleeding persists despite the correct application of conventional methods for hemorrhage control. Plasma-derived coagulation factor hemophilia treatment is considered to be active agents that participate in the coagulation cascade to form fibrin clots and are effective to make an intact coagulation system. Plasma is the liquid part of blood. It is pale yellow or straw-colored with proteins such as antibodies, albumin, and coagulation factors. There are several target factor drug products made from plasma proteins of human. The plasma is collected from group of people, and perform several processes to separate the plasma into its components.

In Italy, according to the data of the National Center for Biotechnology Information (NCBI) in 2017, the number of registered people with bleeding disorders increased from about 7000 in 2000 to around 8500 in 2011 and more than 11,000 in 2015. The trend is due to an upsurge in the number of patients who are recorded, mainly in those with vWD type 1, mild hemophilia, or other factor deficiencies.

Inquiry For Discount @ https://www.theinsightpartners.com/discount/TIPRE00008241/

The report segments the global hemophilia treatment market as follows:

Global Hemophilia Treatment Market By Product

Global Hemophilia Treatment Market By Disease

Global Hemophilia Treatment Market By Treatment Type

Global Hemophilia Treatment Market By Therapy

Global Hemophilia Treatment Market By End User

Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPRE00008241/

About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

MENAFN2505202000703403ID1100221306

Original post:
Hemophilia Treatment Market Analysis, By Key Players, Sale, Trends, Segmentation And Forecast By 2027 - MENAFN.COM

Fact.MR recently published a market study on Gene Therapy. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities & restraints, and detailed information about the Gene Therapy market structure. The market study suggests that the global market size of Gene Therapy is projected to reach a CAGR of xx% over the stipulated timeframe2020-2026.

Key indicators of market growth, which include year-on-year (Y-o-Y) growth of the market, value chain, supply chain analysis, and compounded annual growth rate (CAGR) are explained in Fact.MRs study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the Gene Therapy market during the forecast period.

Request for Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4648

The study is relevant for stakeholders in the Gene Therapy market, including Gene Therapy manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the Gene Therapy market, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in Fact.MRs study.

To know How COVID-19 Pandemic Will Impact This Market/Industry | Request a sample copy of the This Market report:

The study also includes statistics as well as facts related to the macro as well as microeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the Gene Therapy market. Furthermore, small businesses and new entrants in the Gene Therapy market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.

Important regions covered in the Gene Therapy market report include:

The Gene Therapy market report highlights players below:

The global Gene Therapy market report also covers consumption and production of products. The types are as follows:

On the basis of end-use, the report includes:

Key Questions Answered in Fact. MRs Gene Therapy Market Report

Gene Therapy Market: Research Methodology

In Fact.MRs study, a unique research methodology is utilized to conduct extensive research on the growth of the Gene Therapy market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the Gene Therapy market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Send an Enquiry @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4648

Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in the soy protein concentrate market, and makes Fact. MRs projection on the growth prospects of the Gene Therapy market more accurate and reliable.

Choosing Fact.MR Reasons to Stay Ahead of the Curve

Continued here:
COVID-19 Industry Impact: Gene Therapy Analyzed for Forecast Year - The Cloud Tribune

Global Neurologic Disorders Therapeutics Market: Overview

In todays age, neurologic disorders are becoming increasingly common, especially neurodegenerative diseases. According to various studies, the growth of these neurological disorders is spreading rapidly across Europe and other parts of the world. In addition to this, the treatment for such disorders is also very challenging because of the presence of the strictly regulated blood-brain barrier. It is also challenging due to the unique ability to cover the brain from the new therapeutics. Traditional therapeutics, although effective, are still below the optimum level required for efficient treatment. Hence, there is need for finding newer and more effective therapeutics. This has thus given rise to the neurologic disorders therapeutics market.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6000

Global Neurologic Disorders Therapeutics Market: Notable Developments

Some of the notable developments in the global neurologic disorders therapeutics market are listed below:

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6000

Names of other notable players in the global neurologic disorders therapeuticsmarket are listed below:

Global Neurologic Disorders Therapeutics Market: Drivers and Restraints

There are several factors that are influencing the growth of the global neurologic disorders therapeutics market. One of the key driving factors is the increasing advances in the diagnosis of the different neurodegenerative indications. This has helped in increasing the demand for new therapeutics to effectively treat such neurodegenerative disorders. The early determination such disorders is difficult due to its complex nature of such disorders, lack of efficient diagnostics, and its fast progression. This has naturally helped in driving the activities of research and development for more effective treatment. Governments across the globe are also helping research institutes by allotting more funds for the development of new neurologic disorder therapeutics.

Global Neurologic Disorders Therapeutics Market: Geographical Outlook

The global neurologic disorders therapeutics market is primarily divided into five key regions viz. North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. Of these, the global neurologic disorders therapeutics market is primarily dominated by North America region. This is because of the high aging population in the region, advancements in technology, and highly developed healthcare infrastructure.

Get Discount on Latest Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6000

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Original post:
Neurologic Disorders Therapeutics Market Scope and Opportunities Analysis 2018 2028 - Cole of Duty

The Expression Vectors market report on the world market encompasses an evaluation of distinct parameters that uplift the growth of the global industry. In addition to this, all the industry manufacturers can utilize the market report to create themselves for facing tough market challenges and further competition in the universal market. Insightful information on notable strategies adopted by vital firms along with their key impact on the industry growth has been administrated in this market document. This Expression Vectors market research report gives explanation of market restraints, key drivers, and industry trends that transform the international market either in a positive or negative manner.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-expression-vectors-market

Market AnalysisBesides target market information, DBMR also provides information about your competitor, your customers, products etc. A few techniques we use are: Customer analysis Competitor analysis Risk analysis Product research Advertising research E-mail survey and many more

Globalexpression vectorsmarketis set to witness a substantial CAGR of 6.3% in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. The rise in the market value can be attributed to increasing prevalence of infectious diseases, genetic disorders and other lifestyle associated diseases.

Some of the major players operating in globalexpression vectors marketareDNA TwoPointO Inc., Thermo Fisher Scientific, Inc., Promega Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories Inc., QIAGEN, Merck KGaA, TAKARA HOLDINGS Inc., New England Biolabs, GenScript, Quest Diagnostics ,Synbio Technologies, Addgene,Inc., BD, OriGene Technologies, Inc., InvivoGen, GeneCopoeia, Inc., ATCC, tebu-bio, System Biosciences, LLC., Sanofi, transOMIC, Genlantis Inc., Macrogen, Inc. and Gene Bridges GmbH among others.

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-expression-vectors-market

Market Definition: Global Expression VectorsMarket

Expression vector is a vector that is used in genetic engineering which enables a particular gene to be cloned and expressed in a host cell.These vectors are also used in genetics, molecular biology and computer sciences. A specific gene is initiated to enter into a target cell via expression vector. Protein expression is a technique in which proteins are modulated, transformed and synthesized in living organisms or cells.

In2019, the statistics obtained from the American Cancer Societys publication and the National Cancer Institutes Surveillance Epidemiology, is believed that 268,600 women and 2,670 men in the United States will be diagnosed with breast cancer. It is estimated that from breast cancer 42,260 deaths will occur this year.Wide variety of cancers can be treated by multiple gene therapy strategies, including suicide gene therapy and therapeutic gene vaccines.

Segmentation:Global Expression VectorsMarket

Expression Vectors Market : By Host Type

Expression Vectors Market : By Application

Expression Vectors Market : By End User

Expression Vectors Market : ByGeography

Key Developments in the Expression Vectors Market :

Expression Vectors Market : Competitive Analysis:

Globalexpression vectorsmarketis highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares ofexpression vectorsfor Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence and Regulatory Affairs Managers among others.

Opportunities in the Expression Vectors Market Report :

Want Full Report? Enquire Herehttps://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-expression-vectors-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:[emailprotected]

Read the original here:
Covid-19 Impact On Global Expression Vectors Market 2020 : Industry Trends, Size, Growth, Swot Analysis By Top Key Players And Forecast Report To 2026...